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Abstract
Background: Modern cancer treatment strategies aim to target tumour specific genetic (or epigenetic) alterations.
Treatment response improves if these alterations are clonal, i.e. present in all cancer cells within tumours. However,
the identification of truly clonal alterations is impaired by the tremendous intra-tumour genetic heterogeneity and
unavoidable sampling biases.
Methods: Here, we investigate the underlying causes of these spatial sampling biases and how the distribution and
sizes of biopsies in sampling protocols can be optimised to minimize such biases.
Results: We find that in the ideal case, less than a handful of samples can be enough to infer truly clonal mutations.
The frequency of the largest sub-clone at diagnosis is the main factor determining the accuracy of truncal mutation
estimation in structured tumours. If the first sub-clone is dominating the tumour, higher spatial dispersion of samples
and larger sample size can increase the accuracy of the estimation. In such an improved sampling scheme, fewer
samples will enable the detection of truly clonal alterations with the same probability.
Conclusions: Taking spatial tumour structure into account will decrease the probability to misclassify a sub-clonal
mutation as clonal and promises better informed treatment decisions.
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Somatic evolution
Background
In the past years, it has become increasingly clear that
cancers are typically highly heterogeneous and charac-
terised by a large degree of spatial diversity, which compli-
cates cancer therapy [1, 2]. Modern anticancer therapies
aim at targeting tumour-specific genetic and epigenetic
alterations, e.g. by specifically designed molecules [3] or
immuno-therapy [4–6]. The paradigmatic example has
been Chronic Myeloid Leukemia that is driven by the
BCR-ABL oncogene. Tyrosine kinase inhibitors (TKI)
such as Imatinib can inhibit the critical gene driving the
disease leading to long lasting remissions, improved sur-
vival and perhaps even cure in some patients [7–10]. With
rare exceptions [11], this goal to date has not materialized
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for other tumours since in many of them, the appropriate
driver mutations(s) are either unknown, not targetable or
treatment resistant. Although now tumour sequencing is
available commercially and mutations within tumours can
be identified routinely, the clinical benefit of such thera-
pies has been limited, since it is likely that the identified
mutations are not responsible for driving the tumour in
that specific patient [12], or resistance emerges fast after
an initial brief treatment response [13–17]. It is impor-
tant to note that simply because a mutation is ’common’
in a specific tumour type does not make it an appropri-
ate target of therapy. Determining which mutations are
targetable is not simple for a variety of reasons includ-
ing (i) the identified mutations may not be drivers in
that patient, (ii) more than one driver mutation may be
present, (iii) genetic and spatial heterogeneity within the
tumour make it difficult to be reasonably certain that the
truncal/clonal mutations that could be targeted have been
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properly identified, which is the main focus of our work
here.
The accumulation of mutations in a growing tumour
leads to the presence of cells with different mutational
profiles. Classical branching models predict that muta-
tions will be increasingly present at lower frequency [18].
More specifically, late alterations are typically found in
small proportions of cells, whereas early alterations are
expected to be more abundant [19]. For example, muta-
tions present in the first tumour initiating cancer cell
should, in principle, be clonal and consequently found in
every cancer cell of the particular patient. In clinical pro-
tocols, it is often assumed that a mutation that is present
in approximately 50% of the sequencing reads of a sin-
gle tumour bulk sample is likely clonal (after adjusting for
tumour ploidy and tumour purity). However, this reason-
ing is problematic, since it requires that the underlying
sample is representative of the whole tumour. Multi-
region profiling shows that this is not the case [1, 2, 20].
These multi-region sequencing studies have revealed a
muchmore complicated picture of severe inter- and intra-
tumour genetic heterogeneity [1, 2, 21–23]. Mutations
that appear clonal in a single sample can be sub-clonal
or even absent in other samples of the same tumour
[24]. Therefore, targeting such mutations would not be
expected to provide a long term therapeutic benefit as
we would at best treat only the part of the tumour that
contains these sub-clonal mutations.
Indeed, determining which are the truly clonal alter-
ations in a neoplasm that contains billions of cells
distributed in complex spatial patterns is a challeng-
ing problem that has important implications for mod-
ern cancer therapies. Limitations of sequencing depth,
genetic heterogeneity within single samples, contamina-
tion with healthy tissue and loss of genetic elements
due to genome instability, all complicate the classifica-
tion of these alterations [25]. In this regard, multi-region
sequencing has been shown to bemore informative for the
discrimination of mutations than a single bulk sequencing
[1, 18, 26–29]. As multi-region sequencing of tumours
has become feasible, this has led to a development of
a range of phylogenetic methods and tools to construct
phylogenetic trees from cancer and infer truncal (clonal)
mutations [30, 31].
The detailed architecture of any tumour is likely
unique and driven by the complex interactions between
microevolution, the immune response as well as the pres-
ence of physical barriers to growth of the tumour popu-
lation in each specific patient. The latter depends on the
location of the tumour within the body. This complex-
ity makes it difficult to reconstruct the branching process
that underlies the growth of the tumour population. In the
absence of such knowledge, what would be the optimal
sampling approach for each individual tumour and how
can we maximize our probability to identify truly clonal
(and hopefully driver) mutations within these tumours?
This is the focus of our work here.
We have previously shown that it is not necessary to
reconstruct the complete phylogenetic tree of a tumour
to estimate the probability to identify all clonal alter-
ations correctly [20]. It is easier and sufficient to identify
only the earliest branching events, which then allows the
detection of all truly clonal genetic alterations within indi-
vidual tumours. We consider the earliest branching event
that separates sub-clonal mutations from those mutations
present in the ancestral population of cancer cells. We
refer to these branch-defining sub-clonal mutations on
the ancestral population background as first-tier muta-
tions (Fig. 1d). Takingmore samples will naturally increase
the chance to exclude misclassified sub-clonal mutations.
However, this obviously implies a cost-benefit tradeoff
and a proper understanding of the scaling of these proba-
bilities with increasing tumour sample numbers can better
inform treatment strategies.
In our previous work, we showed how the probability to
correctly classify clonal mutations scales with additional
samples and how many samples are needed to identify
the truncal mutations with a certain level of confidence
given the life histories of a tumour [20]. But critically, this
initial study did not consider successive branchings from
the ancestral population, the spatial structures of both the
tumour and the samples as well as the influence of the
sizes of the biopsies taken.
Here, we quantify the probability to correctly classify
the clonal mutations of individual tumours growing in
space with sufficiently low mutation rates per cell divi-
sion (as is for example the case for clinical targeted or
exome sequencing protocols). We also show how the size
of tumour samples influences our ability to identify truly
clonal alterations and how we can increase the accuracy
of the detection by exclusion of low frequency mutations.
We address the problem of spatially structured tumours,
which can have great repercussions on clonality infer-
ences. Finally, we compare different sampling protocols by
comparing standardised spatial sampling patterns against
random sampling. By applying standardised sampling pat-
terns one can further increase the probability to correctly
classify truly clonal mutations.
Methods
Computational model of tumour heterogeneity
We simulate tumours on a lattice where filled nodes rep-
resent the presence of individual tumour cells. For the
structured case, the neighbouring cells are thought to rep-
resent a real – but arguably highly idealized – tumour
architecture. For the unstructured case – often referred
to as the “well mixed” case – the neighbourhood on the
lattice has no relevance for simulations, as any cell can
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Fig. 1 Spatial model of intratumour heterogeneity. a Schematic illustration of our spatial cancer model. Tumour cells are represented as nodes on a
two dimensional lattice. Each cell has a mutational profile. With each cell division, a cell can mutate with probability μ = 0.5 and thus intratumour
heterogeneity is generated. While we typically think of each node as a cell, it could in principle also represent a small subpopulation of cells. b The
mutational profiles of cells within a bulk biopsy are then combined to give the mutational profile of the biopsy sample. Red coloured
subpopulations are cells that carry the first sub-clonal mutation (red in the mutational profile), while blue cells do not contain it. All cells carry one
truncal mutation (blue in the mutational profile). Cells acquire new mutations and are presented with a different nuances of the original colour. In
this example, because the red and blue subpopulations are approximately equal in size, we call the tumour well-balanced. c The different first-tier
sub-clones are spatially represented within the tumour, placed around the centrally positioned ancestral population. d An ancestral population that
contains a set of truncal mutations (blue square) branches multiple times into first-tier sub-clones with their own private sets of mutations. Having
only samples from one of the major branches will result in a misclassification of the sub-clonal mutation that founded that branch
divide and place its offspring to any empty site. Sim-
ulations start by transforming one cell into a tumour
cell through the introduction of the first mutation (in
principle many mutations could be introduced, however
this does not matter for our purpose here). Simulations
run in discrete time steps. During each time step, one
cell is chosen randomly for reproduction. Once chosen,
it divides into one adjacent empty space, if the tumour is
spatially structured, or in any random available place cho-
sen from non-occupied spaces, for a well-mixed tumour.
With each division, one daughter cell accumulates a novel
mutation proportional with probability μ. After division,
one randomly chosen tumour cell will die with a proba-
bility d = 0.1. To simulate a non-aggressive tumour, we
have chosen a lower death rate than suggested by Waclaw
et al. [32] (d = 0.5 x birth rate) for the simulation of highly
aggressive tumours.
Computationally, the tumour is represented by a sparse
matrix, wherein the position of a cell, the ID of its par-
ent cell and the signature identifier of each new mutation
is stored. This information allows us to reconstruct the
mutational profiles of any cell at any given time point.
We assume that each mutation can arise only once during
division and can only be lost when the cell dies (cor-
responding to the infinite allele assumption). Moreover,
we assume all mutations to be neutral – they do not
affect the fitness of the carrier cell. Our assumption of
neutrality should not impact the generalizability of our
results. After a full sub-clonal sweep, the dominant sub-
clone would appear as ancestral population, thus leading
to a tumour population with similar underlying branch-
ing structure. The nature of our simulation makes the
structured tumour grow mostly at its periphery. Once
the centre of the tumour is densely populated cells can
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only divide if neighbouring space becomes available after
a random cell death. This pattern is supported by obser-
vations of similar peripheral growth patterns in some real
tumours [33].
In our analysis only the presence of new mutations is
important and not the number of new mutations in each
cell.We therefore assume that during each division daugh-
ter cells receive a new mutation with probability μ = 0.5.
This assumption is supported by the estimated highmuta-
tion rates in neoplasms. With effective mutation rates
(mutation per surviving lineage) of up to 10−7 mutations
per base per division, we can expect a mutation occurring
during almost every division within the exome of can-
cer cells [19]. With this mutation rate we achieve early
branching and extensive intra-tumour heterogeneity from
the early stages of tumour growth. This feature of the
model is compatible with the fact that only early muta-
tions are likely to spread sufficiently to be detected by
Next Generation Sequencing [29]. Early branching pro-
vides a broad spectrum of sizes of the first sub-clone in
our simulations due to the stochastic nature of sub-clonal
growth and mutation accumulation. At the end of the
simulation we calculate the frequency of each mutation
within the tumour. We specifically denote frequencies of
first tier sub-clonal mutations and the most frequent sub-
clonal mutation. In the evolutionary history of the tumour,
we define the first-tier branch as the subpopulation of
cells that diverged directly from the ancestral popula-
tion of tumour cells. To reconstruct the truncal mutations
from multi-region tumour sampling, we need to either
sample from two different first-tier subpopulations that
emerged from the ancestral cancer population or from
one first-tier subpopulation and the ancestral subpopu-
lation, because sampling from the same first-tier branch
will falsely identify branch-defining mutations as clonal
mutations.
Sampling and clonality inference
A single simulated biopsy is composed of a group of cells
in close proximity (Fig. 4), or a single cell (Fig. 2) initially
taken from a random location of the lattice. In a well-
mixed tumour, due to the absence of spatial structure, a
sample is a number of randomly pooled cells (Fig. 4), or
a single cell (Fig. 2). We reconstruct the mutational pro-
files of the sampled cells and calculate the frequencies
of the mutations within each sample. As we are unable
to detect low frequency mutations with current sequenc-
ing technology (sequencing depth threshold), we vary
the threshold ε to detect a mutation within the sample.
Mutations that appear clonal across a tumour are those
mutations present in all taken samples. However, in our
simulations we know the ground truth and we can test
how often these mutations actually represent truly clonal
mutations present in the first cancer initiating cell. If no
mutations were wrongly classified as clonal we mark our
sampling as correct. Otherwise, if there is at least one
sub-clonal mutation misclassified as clonal, we consider
our sampling incorrect. To get the proportion of correct
estimations for single tumours, we repeat the sampling
process 10 000 times with n samples (shown as dots in
Figs. 2 and 4).
For pattern sampling we chose four single-cell samples
from the tumour edge located at opposite directions and
assessed clonality as previously described. To calculate
the proportion of correct estimations for each individual
tumour using our sampling pattern, we rotated the sam-
ples stepwise and assessed clonality on each step until
we covered the whole tumour circumference (Fig. 6a).
Rotations of the samples allowed us to make multiple
repetitions of sampling on a single tumour using the
same pattern. The proportion of correct estimations was
then compared with random single-cell sampling and our
mathematical model quantification.
Mathematical model
Let us first consider a simple model with only a single
bifurcation representing the entire phylogenetic tree of
the tumour. This bifurcation generates a branching sub-
populations of cells that diverged directly from the ances-
tral populations of initiating tumour cells. This branch
contains a new sub-clonal mutation compared to the
ancestral population. Here we define a balancing factor f
as the proportion of the subpopulation within this branch,
while the proportion of the other branch of the ancestral
population is 1 − f . If we take n independent samples at
random, the probability pf (n) of finding the true clonal
(truncal) alteration is the probability that not all n samples
come from the branch with the new sub-clonal mutation,
in our case this is
pf (n) = 1 − f n. (1)
We now generalize the expression of pf (n) for a phylo-
genetic tree with a large number of bifurcations. Among
all bifurcations, we are specially interested in the branches
that diverged directly from the ancestral population.
These branches are defined as first-tier branches, each
of which contains a distinct sub-clonal mutation com-
pared to the ancestral population (Fig. 1d). Within each
of these first-tier subpopulations, subsequent sub-clonal
mutations would happen constantly (Fig. 1d). However,
these subsequent events are unnecessary for identifying
the truly truncal alteration, so in what follows we ignore
them and focus on the first-tier branches. We assume that
the mutation rate of cells in the ancestral population does
not change over time, so the first-tier branching muta-
tions arrive after equidistant intervals. As a result, the
balance factor f is unchanged and applies to all the first-
tier branching mutations. Suppose there are M first-tier
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Fig. 2 Comparison of clonality inferences in structured and unstructured models of tumours with a different proportion of the largest sub-clone. a
The probability to correctly identify set of truly clonal mutations with n tumour samples in our model. In tumours where the size of the largest
sub-clone f is small (f = 0.1) the probability to correctly identify truly clonal mutations is already sufficiently (>98%) high with two samples. In
balanced tumours with f = 0.5, five samples give the same probability. b The quality of our clonality estimation in dependence of the proportion of
the first sub-clone. Lines represent solutions of the mathematical model, while dots represent results from clonality inferences of spatial computer
simulations. A number of randomly distributed single-cell samples n (n = 2 shown in blue , n = 5 shown in red and n = 10 shown in green) was
taken from each simulated tumour and clonality of present mutations was estimated. Each single dot represents the proportion of correct
estimations for one tumour by sampling n tumour samples after 10 000 repetitions. Results from simulations are in agreement with model
predictions for the full range of f
branches, which are ordered by their time of occurrence.
The proportion of cells in the kth first-tier subpopulation
is f times (1− f )k−1 (the fraction of cells that did not carry
any of the previous k − 1 first-tier sub-clonal mutations).
In this way, the proportions of cells in these first-tier
branches are given by f, (1− f )f , (1− f )2f ,..., (1− f )M−1f .
To identify the true truncal alteration with n independent
samples, these samples should not come from one sin-
gle first-tier subpopulation. Thus, the probability pf (n) is
given by
pf (n) = 1 − f n−[ (1 − f )f ]n −[ (1 − f )2f ]n −
. . .−[ (1 − f )M−2f ]n −[ (1 − f )M−1f ]n .
= 1 − f n
M−1∑
i=0
(1 − f )ni
(2)
If M is sufficiently large, the geometric series can be used
to approximate pf (n) by the simplified expression
pf (n) ≈ 1 − f
n − (1 − f )n
1 − (1 − f )n . (3)
The parameter f, necessary for the calculation of the
probability pf (n) can be estimated from data in the fol-
lowing way: The idea is to compare the sets of clonal
mutations identified by all permutations of tumour sam-
ples. More specifically, first the intersection of all alter-
ations of all n biopsy samples has to be determined. After
that, the intersection of all possible combinations of i = 2
biopsy samples is generated. The frequency at which both
intersections coincide is an estimate for the probability
of a correct classification, pf (i)/pf (n). The same proce-
dure is performed for all possible combinations of i =
3, 4, ...n− 1 biopsy samples. Using these probabilities, one
can estimate f for a given cancer by fitting the estimated
probabilities to
pf (i)
pf (n)
= 1 − f
i − (1 − f )i
1 − (1 − f )i
1 − (1 − f )n
1 − f n − (1 − f )n . (4)
Results
Expectation from our mathematical model
In a highly homogeneous cancer with low mutational bur-
den, even the largest sub-clonal mutation is only present
in a small proportion of the tumor. Thus, our mathe-
matical model predicts a fairly small chance to get false
positive clonal mutations, see Fig. 2a with f = 0.1. Already
with n = 3 samples the probability to correctly clas-
sify truly clonal mutations is > 98%. For the case where
the first branching event leads to a tumour with two
roughly equally-sized populations f = 0.5 (both of which
will carry a tremendous amount of private mutations and
many subsequent branchings) we reach a probability of
> 98% already with n = 6 samples. Finally, in tumours
where specific sub-clonal mutations undergo great expan-
sion, it is highly likely that this expanding mutation and its
sub-clonal mutations will be categorised as clonal (Fig. 2a
with f = 0.9). This is because with increasing f it becomes
less probable to sample from the part of the cancer with-
out that abundant sub-clonal mutation. To reach the same
level of confidence>98%, as in shown tumours with lower
f, we need >38 samples for f = 0.9.
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Validation of the mathematical model using single cell
sampling in simulated tumour
The proportion of the largest sub-clonal mutation f has
a great effect on the clonality analysis. The probability to
correctly classify clonal mutations with n = 2, n = 5
and n = 10 independent samples changes substantially
with the value of f (Fig. 2b). In principle, it is possi-
ble to correctly estimate clonality with only two samples,
in particular if the largest sub-clone is sufficiently small.
Theoretically, two samples give a correct estimation with
probability > 98% for tumours where the proportion of
the largest sub-clonal mutation is below f = 0.1. How-
ever, this probability drops rapidly with increasing f. Using
more samples can substantially increase the probability
of correct clonality assessments. With n = 10 samples,
we cover most of the range of f and only for f > 0.8,
our estimates become less reliable. For most values of
f, 10 random tumour samples are sufficient to reach a
high probability of a correct clonality assessment. We
validate our mathematical model by comparing it with
the results from stochastic spatial simulations of cancer
growth (Fig. 2b for n = 2, 5, 10.). Each point represents
the proportion of correct estimations of clonality inferred
from 10 000 iterations of n independent and random
samples from a single tumour, in which the proportion
of the largest sub-clonal mutation is f. Results obtained
from simulations are in good agreement with our theo-
retical expectation, in particular results with more than
two samples show almost perfect agreement between the
mathematical model and the simulated tumours, despite
the spatial correlations between clones arising in our com-
putational model – which become crucial if we sample
more than one cell.
Effect of the sample size on clonality estimation
Biological samples from tumours typically contain a vari-
ety of different subpopulations of cancer cells, healthy
surrounding and ’supporting’ tissue as well as leukocytes
that infiltrate the tumour. All of these cells can influence
the interpretation of the sequencing data and the correct
assignment of mutations. In current clinical applications,
sequencing a group of cancer cells is standard – with
single-cell genomic profiling so far an approach of the
future. For that reason, we investigated the clonality infer-
ence by using multiple large samples, each containing 1%
of the total number of cells in the tumour. In the previ-
ous analysis of single cell samples, there was nomutational
frequency component – everymutation was of equal value
for the clonality estimation. With multiple cells, we gain
additional information of the frequency for each mutation
within the sample.
Well-mixed tumours
As we previously stated, in our analysis a sub-clonal muta-
tion is misclassified as clonal if it is present in all samples,
therefore to classify it correctly there should be at least
one sample where that mutation is absent. In a well-mixed
tumour, mutational frequencies within large single sam-
ples already represent the spectrum of frequencies within
the whole tumour. That makes them unusable for the clas-
sification of truly clonal mutations from multiple samples
by means of exclusion from multiple sampling, as a large
number of mutations appear clonal if we do not consider
the frequency of eachmutation within the sample.We can
reduce the number of candidate mutations by excluding
mutations with frequency below a certain threshold ε. By
doing so, we remove sub-clonal mutations with low fre-
quencies from the analysis and get a high proportion of
correct estimates (Fig. 3). Bringing the threshold ε above
the frequency of the most abundant sub-clonal mutation
(f ) leads to a correct clonality assessment regardless of
the number of samples. However, such clear demarca-
tion likely is the result of our idealised scenario. In reality
copy number changes and limited sequencing depth shift
frequencies of mutations and introduce additional errors,
leaving some uncertainty for the minimal list of clonal
mutations.
Structured tumours
In structured tumours the clonality inference with mul-
tiple large samples is less accurate than the equivalent
single-cell sample when including all mutations in the
analysis, even though with large samples much more cells
Fig. 3 Effect of sample size on clonality inference in well-mixed
tumour. The proportion of correct clonality estimates for n = 2
samples, each containing 1% of total number of cancer cells. ε
represents the frequency bellow which we discard mutations from
the clonality analysis. The value of ε where identification of clonal
mutations becomes impossible corresponds to the proportion of the
largest sub-clone f, as each sample is representative of the whole
tumour
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are included in the analysis than with single-cell sam-
pling (Fig. 4 for ε = 0). Large samples (1% of tumour
size) contain more sub-clonal mutations that might be
considered clonal. Having the frequency of each muta-
tion within the sample, we can consider all mutations
present at sufficiently low frequency within the sam-
ple as sub-clonal. By doing so we stop considering all
mutations present in every sample as clonal. By raising
the mutation detection threshold ε, low frequency sub-
clonal mutations are removed from the analysis which
increases the accuracy of our classification, ultimately
surpassing the probabilities predicted by our model for
single-cell sampling (Fig. 4). We would get the best results
by considering only mutations that appear clonal within
the sample. Yet, some of clonal mutations might appear
sub-clonal within the samples due to contamination
with healthy tissue, copy number variation or sequenc-
ing noise, and would be wrongly excluded from the
analysis.
To further test our approach, we repeated the same
inference on a spatial model of tumour growth origi-
nally developed by Waclaw et al. [32], shown in Fig. 5.
This model is very different from ours not only in the
dimensionality, but also in many other details of the com-
putational implementation of stochastic tumour growth.
For example, the model is not based on a spatial lattice,
allowing more complex configurations of cells in space.
Nonetheless, the results on this three-dimensional model
show the same qualitative features we observed in our
two-dimensional scenario. The structure of the tumour
has the same effect on the probability to correctly detect
clones, furthermore both size of the samples and removal
of sub-clonal mutations within samples from the analysis
are showing similar trends as in our original computa-
tional implementation.
Clonality inference using non-random spatial sampling
Until now, we only considered a random sampling process.
In reality, this approach is not applicable and it would
be useful to have clearly defined spatial relations between
individual samples. Thus, we now compare the clonality
inference using four samples arranged in a circular spa-
tial pattern (Fig. 6a) against four randomly distributed
samples. We use samples from the (circular) edge of the
tumour with the greatest distance between samples. In
order to calculate the probability for a correct estimation
of clonal mutations for a single tumour, we repeat the
sampling process on the same tumour after we rotate all
samples (Fig. 6a) while maintaining the distance between
them.We find that by sampling in this pattern, we increase
the probability to correctly classify clonal mutations in
tumours across most range of sub-clone proportions, f,
compared to random sampling (Fig. 6b). This is espe-
cially pronounced for intermediate number of samples.
Interestingly, for n > 1/(1 − f ), the classification of
clonal mutations is correct almost with certainty. Only in
cases where the proportion of the largest sub-clone f is
close to 1, random sampling can be superior to pattern
sampling.
These results can be generated to any number of sam-
ples positioned in an equidistant pattern. If we keep the
same distance between samples, to have at least one
sample not containing the largest sub-clonal mutation
(1 − f ), on average we need to sample n = 1/(1 − f ) sam-
ples. This translates to at least 10 samples needed for a
correct classification of clonal mutations for tumours with
f > 0.9.
To test the possibility that improvement in classifica-
tion is caused by specific (unknown) properties of cells
from the edge of tumour and not due to pattern sampling,
we took a series of random samples from the edge of the
Fig. 4 Effect of sample size on clonality inference in spatial tumour. To test the effect of biopsy size, we tested the accuracy of clonality estimations
by sampling groups of cells (one sample = 200 cells, corresponding to 1% of tumour size). Batches of tumour samples (two for a), five for b) and ten
for c)) were taken at random locations and used to estimate the clonality of the present mutations. We repeated sampling process 10 000 times for
on each tumour and calculated proportion of correct estimations – single point on figure. We exclude mutations below a certain frequency ε from
the analysis (ε = 0.0 or no exclusion for red, ε = 0.3 for blue, ε = 0.8 for green), which increases the accuracy of clonality estimations
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Fig. 5 Clonality inference on the three-dimensional, spatial tumour model. To test the robustness of our results, we repeated the clonality inference
process in the previously published spatial cancer model of Waclaw et al. [32], which is very different from our model. Small biopsies (green; one
biopsy = 1 node) have a much greater probability to correctly classify clonal mutations than large biopsies (purple; one biopsy =8% of the total
tumour size) if we include all mutations present in each sample ε = 0.0. As we increase the threshold of the mutation frequency ε (middle panel
ε = 0.3, bottom panel ε = 0.8), the accuracy of larger samples is increasing, and goes beyond single-cell samples and model predictions, same as in
our simpler model. model. Number of tumours = 300 with maximum size of 5 · 106 cells were simulated with a death rate of d = 0.8. Mutation rate
γ = 0.02 mutations per division
Fig. 6 Pattern spatial sampling and identification of clonal mutations. We compared our model (blue line) to simulation results using random
single-cell sampling (red points) and to simulation results using sampling in specific pattern (blue points). Sampling pattern in panel a). Each red
point represents the proportion of correct estimates with n = 4 samples after 10 000 sampling repetitions. For the green points, the template
pattern was rotated to obtain multiple sampling repetitions from each tumour, while maintaining the distance between the cells and the peripheral
location of cells. The proportion of correct estimations was calculated from a number of possible sampling repetitions for each tumour. Sampling in
pattern appears superior to random sampling throughout most of the range of proportion of largest sub-clone f (Fig. b))
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tumour and estimated clonality. These results match those
from purely random sampling.
Discussion
Targeting “driver mutations” in cancer is considered an
important new approach to therapy that takes into consid-
eration a varied mutational landscape present in tumours,
even when arising in the same tissue [34–36]. The
paradigm set by TKI (Tyrosine kinase inhibitors) therapy
of CML (Chronic myelo id leukemia) and ALK inhibition
(Anaplastic lymphoma kinase) in a small subset of patients
with non-small cell lung cancer is quite compelling.
In these two tumours, the mechanistic understanding
of how the mutation drives the tumour is clear and
therefore the term “driver” mutation is justified. Simi-
larly, c-Kit expression on gastrointestinal stromal tumours
(GIST) renders these tumours sensitive to imatinib as are
the rare cases of mastocytosis with eosinophilia due to
PDGFRA expression or mutant c-Kit expression [37–39].
BRAFV600E mutations in malignant melanoma render the
cells sensitive to vemurafenib [40]. Sequencing of other
rare tumours has also led to the discovery of mutations
that can be meaningfully targeted [41]. However, in the
majority of cases, the identification of a mutation by itself
does not imply that it is a driver – even if this was shown to
be the case in a similar tumour and it is present in a signif-
icant fraction of the sample. Clonality needs to be proven
with a reasonable certainty if there is any hope that tar-
geted therapy will be effective. Sequencing a single sample
and inferring that a mutation is “actionable” is fraught
with problems, since the sample of the tumour sequenced
may not be representative of the whole tumour, and in
addition sampling has also to contend with the problems
of false positive and negatives, high background noise due
to the potential presence of not fully malignant cells that
may still harbor normal copies of important genes such
as TP53 [42] as well as contamination with normal tissue.
It is therefore not surprising that despite major efforts,
the practical benefit of NGS sequencing for the individ-
ual patient to date has been limited. A recent example
illustrates this case: In a series of 95 patients with cancer
seen at MD Anderson Cancer Center, NGS sequencing
identified at least one mutation in 92% of patients. The
most common were in TP53 (25%) and KRAS (10%). In
principle, 36% of the tumours sequenced had an action-
able mutation and 13 patients received therapy based on
this sequencing data to target the presumed driver muta-
tion. Four patients had a partial response, six had stable
disease while three progressed [36]. It is difficult to justify
the current clinical approach with these results. Proving
that a mutation is truncal and therefore clonal should lead
to better identification of driver mutations and proper
targeting of suchmutations is more likely to givemeaning-
ful results. It appears that a proper sampling strategy for
multi-region sequencing of a tumour is a key component
in the process for the correct identification of truly clonal
mutations. Such a list that is developed for every unique
patient sequenced will likely be enriched for ’driver’ muta-
tions. In this work, we discuss how to improve the strat-
egy determining this list of clonal mutations with a high
level of certainty. The future introduction of multi-region
tumour profiling into clinical practice requires a better
understanding of the underlying mechanisms of intratu-
mour heterogeneity and a more standardized approach to
tumour sampling. We are still unable to steer the biolog-
ical processes within a tumour to affect its heterogeneity
[43] , but we can optimize the way we collect and analyze
tumour samples.
Our study provides insights into both intrinsic and
extrinsic factors that influence the probability to detect
truly clonal mutations. As the construction of the com-
plete tumour phylogeny is not necessary for clonality
inference, we focused on the reconstruction of the series
of branching events coming from an ancestral popula-
tion. We have developed a mathematical model for the
calculation of the probability for correct identification of
truly clonal mutations frommulti-region sampling of can-
cer with a large number of bifurcations. In that process,
the largest sub-clone is the most relevant factor in the
identification of truly clonal mutations. Its proportion is
a consequence of the time since the emergence of the
first sub-clone. The earlier the first sub-clonal mutation
occurs, the more likely we are to misclassify it as trun-
cal. A large abundance of this first sub-clonal mutation
requires more samples to ensure that at least one sam-
ple does NOT contain that mutation. In addition, if the
first sub-clone is only present in a small proportion of the
tumour, there is a low probability of it being misclassi-
fied as clonal. Our results show that considering multiple
branching events we now see that the probability to cor-
rectly classify mutations is much greater than previously
thought [20].
In solid neoplasms, where cells grow in space, we have
shown that larger samples are more likely to overesti-
mate clonality of some mutations if the analysis include
all mutations present in each sample. It is necessary
to exclude mutations present in low and medium fre-
quency from the analysis. Doing so we not just reach
the same accuracy as we would by single-cell sampling,
but we even increase it substantially. However, exclu-
sion of lower frequency mutations from the analysis
might cause false negative classification of some clonal
mutations whose frequencies are variable within a sam-
ple due to contamination with healthy tissue, duplica-
tion of genetic material within some cancer cells, or
sequencing error. In the presence of other detected
clonal mutations, a false negative error is of less con-
cern than a false positive, as false positives would deprive
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the patient of effective therapy. Decision on the cutoff
for the mutation exclusion must be individually cho-
sen based on the number of available clonal mutation
candidates.
Finally, we bring a theoretical rationale for sampling
in non-random patterns. We showed that placing biop-
sies in pattern equally distant from each other, might
substantially increase the probability to correctly classify
truly clonal mutations when compared with random sam-
pling. We are aware that our computational simulations
of tumour growth are simplified and lack many features
of living systems, such as cell migration in tumours with
more complex growth pattern. There, a different spatial
sampling strategy might be more successful. Our results
provide a rationale for pathologists when taking sam-
ples for multi region tumour sequencing and clinicians
during endoscopic sampling of neoplasms of e.g. gas-
trointestinal tract. By choosing samples with maximum
spread in suggested pattern one maximizes the chances
to correctly classify clonal mutations. We also offer a
way to estimate a level of certainty for a list of detected
clonal mutations which can serve as a guidance to oncol-
ogists in their choice of appropriate target. Our results
provide some considerations for the improved clinical
assessment of targetable mutations in treatment naive
tumours.
Conclusions
In conclusion, the correct classification of clonal (trun-
cal) mutations is of great importance for the success of
anti-tumour therapy. We have shown how the probability
to identify truly clonal mutations depends on sub-clonal
composition of tumour and how many samples one must
take to be able to discern mutation clonality with great
confidence. Furthermore using a computational model
of cancer heterogeneity, we have shown how the size of
biopsies affects the probability to correctly identify clonal
mutations. Finally, we showed that our suggested spatial
sampling pattern is superior to random sampling.
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